Experimental keratitis in rabbits by human HSV-1 variants: prevention and treatment

J Med Virol. 1990 Nov;32(3):148-54. doi: 10.1002/jmv.1890320304.

Abstract

The efficacy of different therapies and vaccine preparations was assessed for treating or preventing herpetic ocular keratitis induced by experimental inoculation in rabbits with two HSV-1 variants that display different pathogenetic potential. Early administration of acyclovir (ACV) promoted fast healing and prevented neurologic involvements: alpha-interferon (alpha-IFN) was less efficient than ACV; combined therapy with both drugs increased the antiviral effects. In an attempt to prevent the disease, rabbits were vaccinated with a slightly pathogenic HSV-1 variant or with a secreted form of an engineered HSV-1 glycoprotein gB (gB-1s) and were subsequently challenged with a highly pathogenic HSV-1 variant. Immunization of rabbits with gB-1s was much more efficient than immunization with live virus in reducing the severity of herpetic keratitis and in preventing CNS disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / therapeutic use*
  • Animals
  • Combined Modality Therapy
  • Interferon Type I / therapeutic use*
  • Keratitis, Dendritic / prevention & control*
  • Keratitis, Dendritic / therapy
  • Rabbits
  • Simplexvirus / immunology*
  • Vaccination
  • Vaccines, Attenuated
  • Vaccines, Synthetic
  • Viral Envelope Proteins / immunology
  • Viral Vaccines*

Substances

  • Interferon Type I
  • Vaccines, Attenuated
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines
  • glycoprotein B, Simplexvirus
  • Acyclovir